Clinical Trial Update: Immunoregulatory Therapy for 2019-nCoV [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for an immunoregulatory therapy targeting 2019-nCoV (PD-1 pathway).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• 2019-novel Coronavirus Disease

Snippet

Sponsor: Southeast University, China | Conditions: 2019 nCoV, PD-1 | Phase 2 | Status: UNKNOWN